HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marc Jacobs inducted into Hall of Fame

This article was originally published in The Rose Sheet

Executive Summary

Clothing designer Marc Jacobs will be given the Hall of Fame Award by the Fragrance Foundation at its FiFi Awards in May, the organization says March 27. Jacobs is being honored for his "playful yet sophisticated" approach to fashion and fragrance, epitomized by his Daisy Marc Jacobs scent, which won Fragrance of the Year at the group's 2008 awards. Marc Jacobs for Women was the first stone in his fragrance house, followed by an eponymous scent for men. "Marc's contribution to the fragrance industry started with his very first signature fragrance and now encompasses many different and delicious aromas all imbued with his personality and flair. He has built a fragrance brand with a broad appeal and brought along with him a whole new generation of loyal fragrance lovers for the ride," says Fragrance Foundation President Rochelle Bloom

You may also be interested in...



Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel